Gastroenteropancreatic (neuro)endocrine neoplasms: The histology report

Digestive and Liver Disease

Volumn 43, Issue SUPPL. 4, 2011, Pages

  Rindi, Guido ^a   Bordi, C ^b   La Rosa, S ^c   Solcia, E ^d   Fave, Gianfranco Delle ^e  

^a FONDAZIONE POLICLINICO UNIVERSITARIO A GEMELLI IRCCS   (Italy)

^b UNIVERSITY OF PARMA   (Italy)

^c Circle Hospital   (Italy)

^d UNIVERSITY OF PAVIA   (Italy)

^e SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Carcinoid; ENETS; Gastroenteropancreatic tract; GIPAD report; Grading; Neuroendocrine tumor; Staging; TNM; WHO 2000

Indexed keywords

CD56 ANTIGEN; CHROMOGRANIN A; KI 67 ANTIGEN; NERVE CELL ADHESION MOLECULE; SOMATOSTATIN RECEPTOR 2; SYNAPTOPHYSIN; TRANSCRIPTION FACTOR CDX2;

ARTICLE; BIOPSY; CANCER GRADING; CANCER STAGING; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; INTESTINE CANCER; METASTASIS; MICROSCOPY; NEUROENDOCRINE TUMOR; PANCREAS CANCER; PRIORITY JOURNAL; STOMACH CANCER;

EID: 79953172225     PISSN: 15908658     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1590-8658(11)60591-4     Document Type: Article

References (22)

1. Plockinger U, Rindi G, Arnold R, et al. Guidelines for the diagnosis and treatment of neuroendocrine gastrointestinal tumours. A consensus statement on behalf of the European Neuroendocrine Tumour Society (ENETS). Neuroendocrinology 2004, 80:394-424.
2. Rindi G, de Herder WW, O'Toole D, et al. Consensus guidelines for the management of patients with digestive neuroendocrine tumors: why such guidelines and how we went about It. Neuroendocrinology 2006, 84:155-157.
3. Rindi G, de Herder WW, O'Toole D, et al. Consensus guidelines for the management of patients with digestive neuroendocrine tumors: the second event and some final considerations. Neuroendocrinology 2008, 87:5-7.
4. Solcia E, Klöppel G, Sobin LH Histological typing of endocrine tumours 2000, Springer-Verlag, New York.
5. DeLellis RA, Lloyd RV, Heitz PU, et al. World Health Organization Classification of Tumours, Pathology and Genetics of Tumours of Endocrine Organs 2004, IARC Press, Lyon.
6. Rindi G, Kloppel G, Alhman H, et al. TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading system. Virchows Arch 2006, 449:395-401.
7. Rindi G, Kloppel G, Couvelard A, et al. TNM staging of midgut and hindgut (neuro) endocrine tumors: a consensus proposal including a grading system. Virchows Arch 2007, 451:757-762.
8. Yao JC, Hassan M, Phan A, et al. One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol 2008, 26:3063-3072.
9. Krenning EP, de Jong M, Kooij PPM, et al. Radiolabeled somatostatin analogues for peptide receptor scintigraphy and radionuclide therapy. Ann Oncol 1999, 10:S23-S29.
10. Volante M, Brizzi MP, Faggiano A, et al. Somatostatin receptor type 2A immunohistochemistry in neuroendocrine tumors: a proposal of scoring system correlated with somatostatin receptor scintigraphy. Mod Pathol 2007, 20:1172-1182.
11. Rosai J Ackerman's Surgical Pathology 1996, Mosby, St. Louis, Baltimore, Boston.
12. Soga J, Tazawa K Pathologic analysis of carcinoids; histologic reevaluation of 62 cases. Cancer 1971, 28:990-998.
13. La Rosa S, Finzi G, Puppa G, et al. Lipid-rich variant of appendiceal well differentiated endocrine tumor (carcinoid). Am J Clin Pathol 2010, 133:809-814.
14. Capella C, La Rosa S, Uccella S, et al. Mixed endocrine-exocrine tumors of the gastrointestinal tract. Semin Diagn Pathol 2000, 17:91-103.
15. Klöppel G, Couvelard A, Perren A, et al. ENETS consensus guidelines for the standards of care in neuroendocrine tumors: towards a standardized approach to the diagnosis of gastroenteropancreatic neuroendocrine tumors and their prognostic stratification. Neuroendocrinology 2009, 90:162-166.
16. Fiocca R, Rindi G, Capella C, et al. Glucagon, glicentin, proglucagon, PYY, PP and proPP-icosa-peptide immunoreactivites of rectal carcinoid tumours and related non-tumour cells. Reg Pep 1987, 17:9-29.
17. Lin X, Saad RS, Luckasevic TM, et al. Diagnostic value of CDX-2 and TTF-1 expressions in separating metastatic neuroendocrine neoplasms of unknown origin. Appl Immunohistochem Mol Morphol 2007, 15:407-414.
18. La Rosa S, Rigoli E, Uccella S, et al. CDX2 as a marker of intestinal EC-cells and related well-differentiated endocrine tumors. Virchows Arch 2004, 445:248-254.
19. Lee WJ, Kim CH, Chang SE, et al. Cutaneous metastasis from large-cell neuroendocrine carcinoma of the urinary bladder expressing CK20 and TTF-1. Am J Dermatopathol 2009, 31:166-169.
20. McCluggage WG, Sargent A, Bailey A, Wilson GE Large cell neuroendocrine carcinoma of the uterine cervix exhibiting TTF1 immunoreactivity. Histopathology 2007, 51:405-407.
21. Cheuk W, Kwan MY, Suster S, et al. Immunostaining for thyroid transcription factor 1 and cytokeratin 20 aids the distinction of small cell carcinoma from Merkel cell carcinoma, but not pulmonary from extrapulmonary small cell carcinomas. Arch Pathol Lab Med 2001, 125:228-231.
22. WHO Classification of tumours of the digestive system 2010, IARC Press, Lyon. F.T. Bosman, F. Carneiro, R.H. Hruban, N.D. Theise (Eds.).